As 2026 draws to a close, beauty M&A remains active despite broader economic uncertainty. While deal volume has been more measured than in previous years, the transactions that did materialize reveal a clear pattern: capital is flowing toward clinically validated brands, premium hair care platforms, and scaled businesses with strong competitive moats.
Unlike prior years, which saw a wave of indie brand acquisitions, 2026 was largely defined by strategic portfolio moves from some of the industry’s largest players. Across skin care, hair care, and luxury beauty, companies pursued scale, strengthened category leadership, and expanded exposure to fast-growing segments such as dermocosmetics, medical-grade skin care, and treatment-driven hair care.
Dermocosmetics Becomes Beauty’s Hottest Battleground
No category attracted more strategic attention in 2026 than dermocosmetics and physician-dispensed skin care.
In September, Puig acquired the remaining 50% stake in ISDIN for approximately €1.2 billion, taking full ownership of one of the world’s fastest-growing dermatologist-recommended skin care brands. The transaction reinforces the growing value being placed on science-backed, medically endorsed skin care.
Private equity remained equally active. In June, Bridgepoint acquired Obagi Medical from Waldencast in a transaction valued at up to $460 million, underscoring continued investor confidence in brands operating at the intersection of dermatology, aesthetics, and skin health.
Strategic investments followed a similar theme. In April, Estée Lauder Companies took a minority stake in 111SKIN, while healthcare-focused private equity firm RoundTable Healthcare Partners acquired Colorescience, signaling growing interest in clinically validated brands with strong physician and aesthetic channel relationships.
Not all activity came through acquisitions. Professional skin care brand Epicutis secured a $25 million growth investment, providing additional capital to support commercial expansion, hiring, and international growth.
Beauty M&A activity in 2026 points to a broader shift in what buyers appear to value in skin care: differentiated science, professional credibility, access to medical and aesthetics channels, and platforms with the potential to expand into adjacent areas of skin health.
The Science-First Watchlist: Brands to Watch as Beauty M&A Moves Into 2027
If 2026 transactions are any indication, science-backed skin care will remain an important area to watch as the industry moves into 2027. Beyond the brands that changed hands this year, several companies stand out because they exhibit characteristics that have increasingly attracted strategic and financial investors.
1. Revision Skincare demonstrates the continued relevance of established physician-dispensed platforms. Its professional relationships, operating scale, and private equity ownership make it another business worth watching as the investment cycle evolves.
2. Hydrinity combines regenerative and hyaluronic-acid positioning with professional aesthetics Its appeal lies in the connection between high-performance skin care, post-procedure use, and injectable-adjacent routines.
3. Ourself reflects the growing intersection of skin care, aesthetics, technology, and longevity. For a potential acquirer, the opportunity would be less about adding another conventional skin care label and more about gaining access to a differentiated innovation platform within the broader medical-aesthetics ecosystem.
4. Plated Skin Science brings an even more technology-led proposition to the watchlist. Built around regenerative skin science and differentiated biological technology, the brand illustrates growing interest in platforms where intellectual property, clinical positioning, and professional credibility combine.
These characteristics do not necessarily signal an imminent transaction. Instead, they represent examples of the attributes most likely to attract capital.
Premium Hair Care Continues to Command Premium Valuations
Hair care also remained one of the most active beauty categories in 2026, particularly among brands built around treatment, repair, and professional credibility.
In March, Henkel agreed to acquire Olaplex for approximately $1.4 billion, expanding its presence in premium and professional hair care. The deal reinforces the attractiveness of brands built around proprietary technology and treatment-led positioning.
The transaction follows L’Oréal’s acquisition of Color Wow in 2025, another example of strategics pursuing high-growth brands that successfully bridge professional endorsement and consumer demand.
At the same time, reports that Wella Company’s filling for IPO suggest renewed confidence in beauty assets and could provide an important test of public market appetite for the sector.
Hair care has evolved beyond maintenance into a premium wellness and treatment category capable of commanding strategic premiums.
Beauty M&A Returns to Scale and Portfolio Consolidation
While clinical skin care and premium hair care dominated headlines, another notable theme was the return of large-scale strategic portfolio moves.
In April, L’Oréal completed its acquisition of Kering Beauté for approximately €4 billion, strengthening its position in luxury beauty and fragrance.
Estée Lauder Companies also agreed to acquire the remaining ownership stake in Forest Essentials, deepening its presence in luxury Ayurvedic beauty and the rapidly growing Indian market.
Meanwhile, the industry closely followed merger discussions between Puig and Estée Lauder Companies. Although the discussions ultimately did not result in a transaction, the fact that such a combination was explored highlights the growing importance of scale, geographic diversification, and category breadth.
Another notable strategic shift came from Unilever, which continued to increase its focus on beauty and wellbeing while simultaneously reducing exposure to slower-growth food assets. The company’s acquisition of wellness brand Grüns reflects a broader trend of consumer goods companies concentrating investment in higher-growth beauty, wellness, and health-adjacent categories while streamlining non-core businesses.
The industry’s largest players are increasingly reshaping portfolios around beauty, wellness, and premium categories while pursuing greater scale and specialization.
If 2026 demonstrated anything, it is that beauty remains highly investable, but capital is flowing toward a narrower set of opportunities. Whether through acquisitions, minority investments, growth capital, or even potential IPO activity, one message is becoming increasingly clear and likely to carry in 2027 and beyond: differentiated science, clinical credibility, and strong consumer loyalty are now among the most important drivers of value creation in beauty.
